Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Morning and Evening Dosing of Inhaled Long-Acting Muscarinic Antagonists for the Prevention of Hospitalization Requiring AECOPD or Death from All Causes - the LAMA by Night Study Utilizing a Comprehensive Nationwide Digital Platform for Recruitment Into a Pragmatic Randomized Controlled Trial Integrated with National Registries to Follow Outcomes

NCT05563675 is registered in ClinicalTrials.gov with Chronic Obstructive Pulmonary Disease Trial Network, Denmark as lead sponsor.

NCT NCT05563675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05563675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Morning and Evening Dosing of Inhaled Long-Acting Muscarinic Antagonists for the Prevention of Hospitalization Requiring AECOPD or Death from All Causes - the LAMA by Night Study Utilizing a Comprehensive Nationwide Digital Platform for Recruitment Into a Pragmatic Randomized Controlled Trial Integrated with National Registries to Follow Outcomes
Lead sponsor
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase
Phase 4
Overall status
Completed
Start date
January 27, 2023
Completion date
June 1, 2024
Enrollment
10,011 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

copd exacerbation